Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCAI-005 in Neovascular Age-related Macular Degeneration
NCT07607561Phase 2Not yet recruiting
- Sponsor
- SCAI Therapeutics
- Start
- Nov 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of axitinib in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by SCAI Therapeutics. Primary endpoint: Central Subfield Thickness at 12 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
axitinib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07607561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607561.